Tag: Servier
Rethinking Pharmaceutical Product Reformulations
This piece discusses pharmaceutical product reformulations and product hopping strategies, along with the impact that antitrust scrutiny may have on innovation incentives. The main...
What the Servier judgment teaches us about market definition under...
February 2019
CPI EU News Column edited by Thibault Schrepel, Sam Sadden & Jan Roth (CPI) presents:
What the Servier judgment1 teaches us about market definition under...
EU: Servier’s €331M pay-for-delay appeal goes to court, 3 years later
Three years after receiving a €331 million ($373 million) fine from European antitrust authorities over a pay-for-delay deal on the blood pressure drug perindopril,...
